Chronic Lymphocytic Leukemia
September 2018 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Chronic Lymphocytic Leukemia abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Chronic Lymphocytic Leukemia. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Chronic Lymphocytic Leukemia. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Chronic Lymphocytic Leukemia every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:The Frequency and Prognostic Value of Neutrophilia in Chronic Lymphocytic Leukemia.
Authors:Levy I, Vadasz Z, Polliack A, Tadmor T
Institution:Internal Medicine B Department, Bnai-Zion Medical Center, Haifa, Israel. Israel. School, Jerusalem, Israel. tamar.tadmor@b-zion.org.il.
Journal:Anticancer Res. 2018 Aug;38(8):4731-4734. doi: 10.21873/anticanres.12780.

2:Diagnosis of Richter transformation in chronic lymphocytic leukemia: histology tips the scales.
Authors:Federmann B, Mueller MR, Steinhilber J, Horger MS, Fend F
Institution:Institute of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tubingen, University of Tubingen, Liebermeisterstr. 8, 72076, Tubingen, Germany. falko.fend@med.uni-tuebingen.de.; Department of Hematology and Oncology, University Hospital and Comprehensive Cancer Center Tubingen, University of Tubingen, 72076, Tubingen, Germany.; Department of Radiology, University Hospital and Comprehensive Cancer Center Tubingen, University of Tubingen, 72076, Tubingen, Germany.
Journal:Ann Hematol. 2018 Oct;97(10):1859-1868. doi: 10.1007/s00277-018-3390-x. Epub 2018 Jun 12.

3:Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Authors:Egle A, Steurer M, Melchardt T, Weiss L, Gassner FJ, Zaborsky N, Geisberger R, Catakovic K, Hartmann TN, Pleyer L, Voskova D, Thaler J, Lang A, Girschikofsky M, Petzer A, Greil R
Institution:Department of Internal Medicine III with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Mullner-Hauptstr. 48, 5020, Salzburg, Austria. r.greil@salk.at.; Salzburg Cancer Research Institute - Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR) and Cancer Cluster Salzburg (CCS), Salzburg, Austria. r.greil@salk.at.; Division of Hematology and Oncology, Laboratory for Molecular Genetics and Diagnostics, Innsbruck Medical University, Innsbruck, Austria.; Centre for Hematology and Medical Oncology, Kepler University Hospital, Linz, Austria.; Department for Internal Medicine IV, Hospital Wels-Grieskirchen, Wels, Austria.
Journal:Ann Hematol. 2018 Oct;97(10):1825-1839. doi: 10.1007/s00277-018-3380-z. Epub 2018 Jun 4.

4:Targeting the tumor promoting effects of adenosine in chronic lymphocytic leukemia.
Authors:Cai Y, Feng L, Wang X
Institution:Department of Hematology, Provincial Hospital Affiliated to Shandong University, No. 324, Jingwu Road, Jinan, Shandong 250021, People's Republic of China. No. 324, Jingwu Road, Jinan, Shandong 250021, People's Republic of China. Electronic address: fenglili1982624@163.com. No. 324, Jingwu Road, Jinan, Shandong 250021, People's Republic of China; Shandong University School of Medicine, Jinan, Shandong 250012, People's Republic of China. Electronic address: xinw@sdu.edu.cn.
Journal:Crit Rev Oncol Hematol. 2018 Jun;126:24-31. doi: 10.1016/j.critrevonc.2018.03.022. Epub 2018 Mar 29.

5:Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Authors:Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP
Institution:From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) - all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) - both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne-Bonn, Cologne, Germany (B.E.); St. James's University Hospital, Leeds (P.H.), and F. Hoffmann-La Roche, Welwyn Garden City (M.B., K.H.) - both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) - all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.).
Journal:N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976.

6:Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.
Authors:Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadhi S, Kasar S, Kater AP, Doorduijn JK, Gao L, Lager JJ, Wu B, Egile C, Kersten MJ
Institution:Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: Jennifer_brown@dfci.harvard.edu. of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA. USA. Cardiff University, Cardiff, UK. Boston, MA, USA. University, Rouen, France. USA. City, KS, USA. Lymphoma and Myeloma Center Amsterdam, Amsterdam, Netherlands. Lymphoma and Myeloma Center Amsterdam, Amsterdam, Netherlands.
Journal:Lancet Haematol. 2018 Apr;5(4):e170-e180. doi: 10.1016/S2352-3026(18)30030-9. Epub 2018 Mar 14.

7:CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.
Authors:Cramer P, von Tresckow J, Bahlo J, Engelke A, Langerbeins P, Fink AM, Fischer K, Wendtner CM, Kreuzer KA, Stilgenbauer S, Bottcher S, Eichhorst B, Hallek M
Institution:Department I of Internal Medicine & Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital Cologne, Cologne, Germany.; Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases & Tropical Medicine, Klinikum Schwabing, Munich, Germany.; Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany.; Department III of Internal Medicine, University Hospital Rostock, Rostock, Germany.; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.
Journal:Future Oncol. 2018 Mar;14(6):499-513. doi: 10.2217/fon-2017-0442. Epub 2018 Feb 21.

8:Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia.
Authors:Wang WT, Zhu HY, Wu YJ, Xia Y, Wu JZ, Wu W, Liang JH, Wang L, Fan L, Li JY, Xu W
Institution:Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China. xuwei10000@hotmail.com.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. xuwei10000@hotmail.com.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. xuwei10000@hotmail.com.
Journal:J Cancer Res Clin Oncol. 2018 Mar;144(3):449-457. doi: 10.1007/s00432-017-2568-2. Epub 2018 Jan 3.

9:Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.
Authors:Dartigeas C, Van Den Neste E, Leger J, Maisonneuve H, Berthou C, Dilhuydy MS, De Guibert S, Lepretre S, Bene MC, Nguyen-Khac F, Letestu R, Cymbalista F, Rodon P, Aurran-Schleinitz T, Vilque JP, Tournilhac O, Mahe B, Laribi K, Michallet AS, Delmer A, Feugier P, Levy V, Delepine R, Colombat P, Leblond V
Institution:Hematologie et Therapie Cellulaire, Hopital Bretonneau, CHU Tours, Tours, France. Electronic address: c.dartigeas@chu-tours.fr. Belgium. Roche Sur Yon, France. Pessac, France. Normandie, Rouen, France. U1138, Universite Paris 6, Paris, France. Clermont-Ferrand, Clermont-Ferrand, France. Berard, Lyon, France. Champagne-Ardenne, Reims, France. Vandoeuvre-les-Nancy, France. Universite Paris 13, Bobigny, France. Tours, France.
Journal:Lancet Haematol. 2018 Feb;5(2):e82-e94. doi: 10.1016/S2352-3026(17)30235-1. Epub 2017 Dec 20.

10:Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia.
Authors:Casado LF, Hernandez JA, Jarque I, Echave M, Casado MA, Castro A
Institution:Haematology and Hemotherapy Service, Hospital Virgen de la Salud, Toledo, Spain. Madrid, Spain.
Journal:Eur J Haematol. 2018 Mar;100(3):264-272. doi: 10.1111/ejh.13007. Epub 2018 Jan 17.

11:Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Authors:Thompson PA, Burger JA
Institution:a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA. Houston , TX , USA.
Journal:Expert Opin Investig Drugs. 2018 Jan;27(1):31-42. doi: 10.1080/13543784.2018.1404027. Epub 2017 Nov 15.

12:Advances in chronic lymphocytic leukemia pharmacotherapy.
Authors:Gomes LC, Ferrao ALM, Evangelista FCG, de Almeida TD, Barbosa RC, Carvalho MDG, de Paula Sabino A
Institution:Departamento de Analises Clinicas e Toxicologicas, Faculdade de Farmacia, Universidade Federal de Minas Gerais, Address: 6627, Presidente Antonio Carlos Ave, Pampulha, Zip Code 31270-901, Belo Horizonte, MG, Brazil. Electronic address: adriansabin01@gmail.com.; Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Address: 6627, Presidente Antonio Carlos Ave, Pampulha, Zip Code 31270-901, Belo Horizonte, MG, Brazil.
Journal:Biomed Pharmacother. 2018 Jan;97:349-358. doi: 10.1016/j.biopha.2017.10.105. Epub 2017 Nov 6.

13:Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies.
Authors:Khan M, Siddiqi R, Thompson PA
Institution:Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd, Houston, TX, 77030-4009, USA. Holcombe Blvd, Houston, TX, 77030-4009, USA. pathompson2@mdanderson.org.
Journal:Ann Hematol. 2018 Jan;97(1):1-15. doi: 10.1007/s00277-017-3149-9. Epub 2017 Oct 23.

14:Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
Authors:Sandoval-Sus JD, Chavez JC, Dalia S, Naqvi SMH, Talati C, Nodzon L, Kharfan-Dabaja MA, Pinilla-Ibarz J
Institution:a H. Lee Moffitt Cancer Center and Research Institute, University of South Florida , Tampa , FL , USA. Institute , Tampa , FL , USA. and Research Institute , Tampa , FL , USA. Florida , Tampa , FL , USA. Institute , Tampa , FL , USA. and Research Institute , Tampa , FL , USA. Institute , Tampa , FL , USA.
Journal:Leuk Lymphoma. 2018 Jan;59(1):59-68. doi: 10.1080/10428194.2017.1323271. Epub 2017 Jun 22.

15:Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
Authors:Wendtner CM, Gregor M
Institution:a Klinikum Schwabing, Department of Internal Medicine I , Academic Teaching Hospital of University of Munich , Munich , Germany.
Journal:Leuk Lymphoma. 2018 Feb;59(2):300-310. doi: 10.1080/10428194.2017.1330474. Epub 2017 Jun 1.

For a FREE PREVIEW of the Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Chronic Lymphocytic Leukemia...
at a Special 20% Discount


Medifocus Guidebook on Chronic Lymphocytic Leukemia

Updated: July 2, 2018
219 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Chronic Lymphocytic Leukemia is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

CL63262663

Coupon Expires: December 20, 2018



What Our Customers Are Saying...

"I was recently diagnosed with CLL and searched all over the Web for information. I found the MediFocus Guidebook on Chronic Lymphocytic Leukemia to be a very useful resource. The information about chemotherapy was most important to me as well as recent studies concerning general treatments for this condition. The most valuable information was contained in the extensive references listed which were easy to access with a simple 'mouse' click. You are welcome to use my name as a reference."
G.C.
Coedpoeth, United Kingdom



  
Medifocus Digest Alert is published by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2018 Medifocus, Inc. All rights reserved.